11/15/2019  9:59:59 PM Chg. -0.51 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
75.04USD -0.67% 60,529
Turnover: 4.54 mill.
-Bid Size: - -Ask Size: - 13.38 bill.USD 0.00% -

Business description

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
 

Management board & Supervisory board

CEO
Jean-Jacques Bienaimé
Management board
Dan Spiegelman, Amy Wireman, Dr. Brinda Balakrishnan, Dr. Robert A. Baffi, G. Eric Davis, Henry J. Fuchs, Jeff Ajer, Lon Cardon, Philip Lo Scalzo
Supervisory board
Jean-Jacques Bienaimé, David Pyott, Dr. Alan J. Lewis, Dr. Dennis J. Slamon, Dr. Elaine J. Heron, Dr. V. Bryan Lawlis, Elizabeth Anderson, Michael Grey, Richard A. Meier, Robert Hombach, Willard H. Dere
 

Company data

Name: Biomarin Pharmaceutical Inc.
Address: 770 Lindaro Street,San Rafael, California 94901, USA
Phone: +1-415-506-6700
Fax: +1-415-3827889
E-mail: -
Internet: www.bmrn.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 46.70%
IPO date: 7/1/1999

Investor relations

Name: Traci McCarty
IR phone: +1-415-455-7558
IR Fax: -
IR e-mail: IR@BMRN.com

Main Shareholders

Freefloat
 
46.70%
Capital Research Global Investors
 
10.26%
The Vanguard Group
 
8.71%
PRIMECAP Management Company
 
7.96%
BlackRock, Inc.
 
7.61%
Prudential Financial, Inc.
 
6.56%
Jennison Associates LLC
 
6.50%
AMCAP Fund
 
5.70%